Apricus Biosciences, Inc. (APRI)
11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041
Apricus Website: http://www.apricusbio.com/index.html
NexACT® - Multi-Route Drug Delivery Technology NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.
This technology is useful for:
The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013. Vitaros has been launched in all European Union countries by partner pharmaceutical companies. Additional agreements for marketing Vitaros have been established. For more information see the company's most recent 10K SEC filing.
- Penetrating, proprietary, topical & transdermal formulations.
Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
Delivering siRNA therapeutics into the cells; in vivo validated
Development of more effective, penetrating cosmeceutic formulations
In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S. The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016. For more information see the company's most recent 10K SEC filing. The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.
In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism. In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
Tel: +1-858 222-8041
The Trout Group
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp